Analytical Method Development and Validation Protocol for Antiepileptic Agent – Rufinamide
Keywords:Antiepileptic, Method development, RP-HPLC, Rufinamide, Validation
This study developed and validated a new, sensitive, appropriate, clear, accurate, and robust reversed-phase high-performance liquid chromatography (RP-HPLC) method for determining Rufinamide in bulk medication and tablet formulation. The separation was performed using an HPLC method with a UV detector and Openlab EZ chrome workstation programme, Kromasil C18, 250 mm X 4.6mm ID, 5 μm column, Methanol: 0.025% TFAA (60:40%V/V) was pumped at a flow rate of 1.0 mL/min and detected at 212 nm. The new RP-HPLC method resulted in a 3.22minute retention time for Rufinamide, which was optimized by trial and error. Over a concentration range of 0.5-7.5 μg/mL, the linearity of the established method was confirmed with a correlation coefficient (r2) of 0.99994. The precision of the approach was determined to have a percentage RSD of less than 2.0 percent. The % recoveries were found to be within the acceptable range. The LOD and LOQ were determined to be 0.10 ug/mL and 0.31 ug/mL, respectively. The developed and validated RP-HPLC system takes less time and can be used in the industry for routine quality control/analysis of bulk drug and marketed Rufinamide products.
How to Cite
Copyright (c) 2022 Gayatri Kakad, Sandhya L. Borse, Atul R. Bendale, Laxmikant B. Borse, Vaishali D. Naphade, Anil G. Jadhav
This work is licensed under a Creative Commons Attribution 4.0 International License.
Asian Pacific Journal of Health Sciences applies the Creative Commons Attribution (CC-BY) license to published articles. Under this license, authors retain ownership of the copyright for their content, but they allow anyone to download, reuse, reprint, modify, distribute and/or copy the content as long as the original authors and source are cited. Appropriate attribution can be provided by simply citing the original article.